Search | Clinical Trials Finder

Conditions: Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fluorouracil, gemcitabine hydrochloride, leucovorin calcium; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions: Temoporfin, Therapeutic Conventional Surgery, Photodynamic Therapy, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions: GoC intervention; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: New Haven, Connecticut • New York, New York

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration; Behavioral · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: nicotine, Usual Care; Drug · Behavioral
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 19 Years to 120 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer, Lung Neoplasms/Diagnosis
Interventions: MyLungHealth, DecisionPrecision+; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 50 Years to 79 Years
Enrollment: 31,303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New York, New York • Salt Lake City, Utah

Conditions: Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 1,559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine lozenge, nicotine patch; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: zinc oxide; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 120 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Solid Tumors
Interventions: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more

Conditions: Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions: Carboplatin, Cisplatin, Palbociclib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lung Cancer
Interventions: Ablation, Surgical Resection; Device · Procedure
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Providence, Rhode Island

Conditions: Solid Tumors and Hematologic Malignancy
Interventions: INCB054329 Monotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions: virtual bronchoscopy; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • White River Junction, Vermont

Conditions: Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions: tumor specimens; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Harrison, New York • New York, New York

Conditions: Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions: WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique; Biological · Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions: 177Lu-DOTATOC; Drug
Lead sponsor: Excel Diagnostics and Nuclear Oncology Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Interventions: Decitabine, Depsipeptide, Celecoxib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Search by objective public record fields.

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Improving Goals of Care Discussion in Advanced Cancer Patients

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Acceptability of Less Harmful Alternatives to Cigarettes

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Zinc Supplements in Lowering Cadmium Levels in Smokers

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Diagnostic Effectiveness of Virtual Bronchoscopy

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Clinical and Histopathologic Characteristics of BAP1 Mutations

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)